2023 February 2 release

In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.

Added entries:

• (FDA) ERBB2 copy number amplifications and sensitivity to trastuzumab in combination with tucatinib in colorectal cancer.
• (FDA) ESR1 somatic variants and sensitivity to elacestrant in breast cancer.

2023 January 5 release

In this release, we add two recent precision oncology approvals from the FDA.

Added entries:

• (FDA) IDH1 p.R132C, p.R132G, p.R132H, p.R132L, and p.R132S and sensitivity to olutasidenib in acute myeloid leukemia.
• (FDA) KRAS p.G12C and sensitivity to adagrasib in non-small cell lung cancer.

2022 December 1 release

In this release, we have removed neoantigen burden as a cataloged feature type and combined Silencing with Knockdown feature types. We additionally expanded upon fields required for each feature type within our S.O.P.

Added entries:

• (FDA) RET fusions and sensitivity to selpercatinib in any solid tumor.

Revised entries:

• (Preclinical) PPARGC1A knockdown with CRSPR-Cas9 and not favorable prognosis in melanoma was changed from the feature type Silencing to Knockdown.
• (Preclinical) USP11 knockdown with siRNA and sensitivity to olaparib in osteosarcoma was changed from the feature type Silencing to Knockdown.

Removed entries:

• (Clinical evidence) High Neoantigen Burden and sensitivity to pembrolizumab in non-small cell lung cancer.

2022 October 6 release

Added entries:

• (FDA) FGFR2 rearrangements and sensitivity to futibatinib in intrahepatic cholangiocarcinoma.

Revised entries:

• (Clinical evidence) SPOP variants and favorable prognosis in prostate adenocarcinoma was changed to sensitivity to abiraterone. Additionally, the doi url was revised to correctly point to the citation.

2022 September 8 release

Added entries:

• (FDA) FGFR1 rearrangements and sensitivity to pemigatinib in myeloid/lymphoid neoplasms.

2022 August 4 release

Added entries:

• (FDA) ALK-EML4 and sensitivity to crizotinib in inflammatory myofibroblastic tumors.
• (Clinical trial) BRCA1 and BRCA2 germline variants and sensitivity to olaparib.
• (Clinical evidence) BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to olaparib in uterine leiomyosarcoma.
• (Clinical evidence) CDKN2A deletion and sensitivity to palbociclib in uterine leiomyosarcoma.
• (Clinical evidence) MYOCD amplification as a diagnostic for strong smooth muscle differentiation in leiomyosarcoma.
• (Preclinical) RB1 copy number deletion and somatic variants and sensitivity to olaparib and talazoparib in prostate cancer.
• (Preclinical) RB1 knockout and resistance to palbociclib in prostate cancer.
• (Preclinical) USP11 silencing and sensitivity to olaparib in osteosarcoma.
• (Inferential) ATRX copy number deletions and poor prognosis in leiomyosarcoma.
• (Inferential) BRCA1 and BRCA2 copy number deletion and loss-of-function somatic variants and sensitivity to PARP inhibition (KU0058684, KU0058948).
• (Inferential) CDKN2C deletion may confer sensitivity to CDK4/6 inhibitors.
• (Inferential) MAP2K4 and MAPK7 copy number amplification and not sensitive to chemotherapy as well as poor prognosis in osteosarcoma.
• (Inferential) PDGFRA copy number amplification and poor prognosis in breast cancer.
• (Inferential) PTEN copy number deletion and poor prognosis in uterine leiomyosarcoma.
• (Inferential) PTEN copy number deletion and sensitivity to sapanisertib in combination with alpelisib in uterine leiomyosarcoma.

2022 July 7 release

Added entries:

• (FDA) BRAF p.V600E and sensitivity to dabrafenib in combination with trametinib in any solid tumor.
• (FDA) IDH1 p.R132C, p.R132H and sensitivity to ivosidenib either with azacitidine or as a monotherapy in acute myeloid leukemia.
• (FDA) MSI-H and sensitivity to pembrolizumab in endometrial carcinoma.

2022 March 3 release

Revised entries:

• (FDA) KRAS p.G12C and sensitivity to sotorasib's description was revised to remove underscores.
• (Preclinical) KRAS somatic variants and sensitivity to FGFR1 inhibitor + trametinib was revised to remove a trailing space from the therapy name.

2021 November 4 release

Added entries:

• (FDA) BCR-ABL1 and sensitivity to asciminib in chronic phase chronic myeloid leukemia.
• (Clinical evidence) SPOP missense somatic variants and favorable prognosis in de-novo metastatic castration-sensitive prostate cancer.
• (Clinical evidence) SPOP missense somatic variants and sensitivity to abiraterone in metastatic castration-resistant prostate cancer
• (Clinical evidence) SPOP missense somatic variants and sensitivity to anti-androgen therapy.
• (Inferential) CD274 amplification and sensitivity to atezolizumab in non-small cell lung cancer.

Revised entries:

• (FDA) FGFR2 fusions and sensitivity to erdafitnib's description was revised to match the standard's described in our S.O.P..

2021 October 7 release

Added entries:

• (FDA) EGFR exon 20 insertion variants and sensitivity to mobocertinib in non-small cell lung cancer.

Revised entries:

• (FDA) BRCA1/2 pathogenic germline variants and sensitivity to talazoparib was revised to properly cite the package insert and correct a spelling error in the description.
• (FDA) BCR-ABL1 and sensitivity to bosutinib in chronic myelogenous leukemia was revised to update the hyperlink for the package insert.
• (FDA) BRAF p.V600E and sensitivity to encorafenib in melanoma was revised to update the hyperlink for the package insert.
• (FDA) TMB-High and sensitivity to pembrolizumab in any solid tumor was revised to correct a spelling error in the description.